3. Management After Coronary Artery Bypass Grafting

Quick Recap

1. Definition

CABG is the most commonly performed cardiac operation, relieving angina and preventing myocardial infarction by bypassing narrowed/occluded coronary arteries — using a pedicled arterial graft (typically the left internal mammary artery, LIMA, which brings its own blood supply from the subclavian artery) or a free graft (saphenous vein or radial artery, requiring anastomosis to a nearby oxygenated source, usually the ascending aorta). Performed on-pump (cardioplegic arrest) or off-pump (beating heart).

2. Postoperative Myocardial Ischemia — A Structured Differential

The heart should not be ischemic after CABG. New ECG ischemic changes should prompt consideration of:

• Myocardial damage from poor intraoperative protection or coronary compromise
• Incomplete revascularization — a segment of myocardium remains ischemic; more common in off-pump surgery, where the ungrafted territory is left entirely unprotected
• Technical graft problem — thrombosis, occlusion, or kink
• Coronary or graft vasospasm

Coronary/Graft Vasospasm — A Genuinely Difficult Diagnosis

• Etiology remains unclear; can affect native, diseased, bypassed, or the bypass conduits themselves (especially arterial conduits)
• Classic trigger: a catecholamine surge, such as waking or extubation, or following vasopressor administration
• Consider this diagnosis in any patient with ECG ischemia, dysrhythmia, or low cardiac output — even when the surgeon is confident about graft quality (the source text's own memorable phrasing: "never trust the surgeon" — confidence in technical execution does not exclude a physiological process like spasm)
• Initial management is supportive: optimize preload, heart rate, contractility, afterload first
• Be careful with nitrates/calcium channel blockers: both are negatively inotropic and can precipitate a further MAP fall by dropping SVR
• If inotropic support is needed, a phosphodiesterase inhibitor (e.g., milrinone) is the agent of choice — it also produces coronary vasodilation, directly addressing the spasm mechanism rather than just supporting output
• Diagnosis confirmed on contrast coronary angiography; lack of hemodynamic improvement should prompt a return to the OR to exclude a technical graft problem rather than persisting with medical therapy alone

Other Specific Causes

• Low intraoperative conduit flow from poor surgical technique should prompt immediate anastomosis reconstruction, not a wait-and-see approach
• Intracoronary air embolism produces ischemic changes that usually resolve spontaneously within minutes — a genuinely reassuring, self-limited cause worth recognizing so as not to over-treat it

3. Conduit-Specific Pharmacology

• Radial artery grafts: diltiazem is often used for the first few months specifically to prevent spasm and graft occlusion
• Vein graft patency: improved by early antiplatelet therapy; vein grafts may be preferable in patients with poor LV function given the reduced requirement for vasoactive drugs these conduits carry

Dual Antiplatelet Therapy — A Genuinely Mixed, Still-Evolving Evidence Base

• CASCADE trial: clopidogrel added to aspirin showed no improvement in SVG patency or intimal hyperplasia versus aspirin alone
• DACAB trial: ticagrelor plus aspirin did improve 1-year SVG patency versus aspirin alone; ticagrelor monotherapy was not superior; major bleeding was infrequent (though the study was underpowered for bleeding/clinical outcomes)
• POPular CABG and TARGET trials: both failed to show additional patency benefit from extending/intensifying P2Y12 inhibition, and observed higher bleeding risk
• A large observational cohort: DAPT with clopidogrel was associated with a 39% mortality reduction and 50% lower stroke risk at 6 months versus aspirin alone — a striking effect size from observational (not randomized) data, worth treating with appropriate caution given the study design
• TOP-CABG trial (2023-2026): 3-month ticagrelor-based DAPT was noninferior to 12-month DAPT for SVG patency; de-escalating to aspirin monotherapy after 3 months significantly reduced clinically relevant bleeding without increasing ischemic events — among the more actionable, practice-relevant recent findings, suggesting shorter DAPT duration may capture most of the patency benefit with less bleeding cost
• Practical synthesis: aspirin monotherapy remains the guideline cornerstone for stable post-CABG patients given the genuinely inconsistent trial results for added P2Y12 inhibition; where DAPT is used (e.g., for a concurrent ACS indication), the TOP-CABG data suggests a shorter (3-month) duration with de-escalation to aspirin alone is a reasonable, evidence-supported approach rather than defaulting to a full 12 months

4. Minimally Invasive and Hybrid Approaches

• MIDCAB (minimally invasive direct coronary artery bypass): usually off-pump LIMA-to-LAD anastomosis via anterior thoracotomy — epicardial pacing wires are not routinely placed, so symptomatic bradycardia may occasionally require temporary transvenous pacing
• Hybrid procedures (MIDCAB plus staged PCI to other vessels): remember these patients are incompletely revascularized in the interim between the two procedures — relevant context if ischemic symptoms/ECG changes occur before the PCI stage is completed

5. Donor Harvest Site Complications

Major free-graft harvest sites are the leg (saphenous vein) and forearm (radial artery, usually non-dominant side). The harvest site is sometimes more painful than the sternotomy itself ("heart surgery is often a pain in the leg"). Complications include pain, paresthesia, bleeding, dehiscence, and infection — risk increased by patient factors (obesity, diabetes, PVD) and operative factors (poor technique, nerve injury, hematoma). Wound infection requires prompt antibiotic therapy, debridement, and negative-pressure dressing as needed.

6. Illustrative Case — Tamponade From an Unexpected Source, and a Genuinely Instructive Wrong Turn

A real case from the source text: a 68-year-old woman, uncomplicated urgent CABG (LIMA + SVG), weaned off bypass without inotropes. Drain output starts at 200mL/h, then progressively falls to 150, 50, and finally 0 mL/h over several hours — interpreted at the time as reassuring ("bleeding has stopped"). Meanwhile her BP steadily drifts down despite fluid boluses, HR rises to 124, and RAP climbs to 16. Norepinephrine is started for the hypotension — with little effect. A PA catheter reveals cardiac index 1.9 L/min/m² with elevated PAOP (19mmHg) — classic low-output/tamponade physiology. TEE confirms a large pericardial collection compressing the right atrium and ventricle. Reoperation finds an arterial bleeding point at the LIMA harvest site on the anterior chest wall (not a coronary graft problem at all) — she recovers uneventfully after control of bleeding.

Learning points, worth internalizing directly:

• An abrupt drop in drain output, especially following a period of significant drainage, can paradoxically be BAD news, not reassuring — the drains may simply be blocked, not the bleeding having genuinely stopped
• The combination of hypotension, elevated filling pressures, and compensatory tachycardia should prompt tamponade suspicion — and note that RAP rise can be LATE, since an open pleural cavity (as in this case, a left pleural drain was present) can accommodate substantial hemorrhage before the heart itself becomes compressed
• Any cardiac surgical patient with rising inotrope/vasopressor requirements and rising filling pressures without a clear explanation for worse cardiac function should be presumed to have tamponade until proven otherwise
• The norepinephrine choice here was actively wrong, not merely ineffective: norepinephrine raises SVR, contractility, and heart rate — appropriate for low-SVR distributive shock (e.g., septic shock), but this patient's hypotension was from low cardiac output with an already-elevated SVR, which norepinephrine would only worsen further, directly increasing myocardial oxygen demand while dropping organ perfusion — if the diagnosis is uncertain, float a PA catheter early and select therapy based on the actual hemodynamic profile rather than defaulting to a vasopressor
• Routine chest radiography, even when not immediately performed after surgery in many units, would have shown a wide mediastinum and fluid-filled left chest in this case — a reminder that indications for chest imaging extend beyond assessing ventilation alone
• Reoperation indications: bleeding, low cardiac output state with suspected tamponade, or cardiac arrest — reexploration itself carries increased morbidity, mortality, length of stay, and sternal wound infection risk, but delaying it when genuinely indicated is the greater risk

7. Consultation Matrix

8. Documentation & Medicolegal Checklist

• Graft conduits used (LIMA, SVG, radial) and any intraoperative flow concerns documented
• Antiplatelet regimen and planned duration documented, with rationale if extending beyond aspirin monotherapy
• Hemodynamic trend and reasoning for vasopressor/inotrope selection documented, particularly when tamponade is part of the differential

9. Key Guidelines

• Current guidance (ACC/AHA, ESC) supports aspirin monotherapy as the cornerstone post-CABG antiplatelet strategy for stable patients, given inconsistent trial support for routine added P2Y12 inhibition; DAPT duration in patients with an independent indication increasingly supported by shorter-course, de-escalation strategies (TOP-CABG)

10. Landmark Evidence

11. Controversies

• The DAPT-after-CABG evidence base remains genuinely inconsistent across trials (CASCADE negative, DACAB positive, POPular CABG/TARGET negative) — this protocol treats aspirin monotherapy as the appropriately conservative default for stable patients, with shorter-duration DAPT (per TOP-CABG) as the more evidence-supported approach when DAPT is used for an independent indication, rather than presenting any single trial as having settled the question.
• The observational 39% mortality reduction with clopidogrel DAPT is a striking figure that should be interpreted with real caution given its non-randomized design — residual confounding (healthier patients more likely to be prescribed and adherent to DAPT) is a plausible alternative explanation not fully excluded by this study design alone.

12. References

1. Nashef SAM, Drury NE, Brettenfeldt N. Management after coronary artery bypass grafting surgery. In: Klein AA, Vuylsteke A, Nashef SAM, eds. Core Topics in Cardiothoracic Critical Care. Cambridge: Cambridge University Press; 2008:373-375.
2. Hirsch WS, Ledley GS, Kotler MN. Acute ischemic syndromes following coronary artery bypass graft surgery. Clin Cardiol. 1998;21:625-632.
3. Kulik A, et al. CASCADE trial data.
4. Zhao Q, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting (DACAB). JAMA Surg. 2018.
5. TOP-CABG Trial: Defining the Optimal Duration of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting. American College of Cardiology, 2026.
6. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing CABG. J Am Heart Assoc.
7. Antiplatelet therapy around CABG: the latest evidence. Curr Opin Cardiol. 2023.

See also: Management After Valve Surgery (this section) for the general prosthetic/anticoagulation framework; Bedside Resternotomy & Tamponade in the Cardiac Surgery ICU (this section) for the emergency response to the tamponade scenario in Section 6; Vasoplegic Syndrome After Cardiac Surgery (this section) for the broader vasodilatory shock differential this case's norepinephrine error illustrates the importance of getting right.